Production (Stage)
GenSight Biologics S.A.
GSGTF
$0.24
-$0.08-25.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 244.52% | 247.40% | -30.65% | -29.01% | 37.38% |
| Total Other Revenue | -9.73% | -7.96% | -45.64% | -44.35% | -48.68% |
| Total Revenue | 258.13% | 265.26% | -37.09% | -35.60% | -57.44% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 258.13% | 265.26% | -37.09% | -35.60% | -57.44% |
| SG&A Expenses | -41.67% | -40.50% | -64.05% | -63.19% | -17.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.28% | -26.84% | -54.42% | -53.34% | -17.46% |
| Operating Income | 33.91% | 32.58% | 57.17% | 56.16% | 15.90% |
| Income Before Tax | 43.50% | 42.36% | 51.69% | 50.55% | 11.13% |
| Income Tax Expenses | 872.73% | 900.00% | 145.45% | 145.45% | -155.00% |
| Earnings from Continuing Operations | 43.38% | 42.24% | 51.66% | 50.51% | 11.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.38% | 42.24% | 51.66% | 50.51% | 11.16% |
| EBIT | 33.91% | 32.58% | 57.17% | 56.16% | 15.90% |
| EBITDA | 25.73% | 24.23% | 55.83% | 54.78% | 23.56% |
| EPS Basic | 73.65% | 73.16% | 73.07% | 72.41% | 18.61% |
| Normalized Basic EPS | 73.76% | 73.20% | 73.10% | 72.41% | 18.54% |
| EPS Diluted | 73.65% | 73.16% | 73.07% | 72.41% | 18.61% |
| Normalized Diluted EPS | 73.76% | 73.20% | 73.10% | 72.41% | 18.54% |
| Average Basic Shares Outstanding | 115.12% | 115.12% | 79.29% | 79.60% | 9.12% |
| Average Diluted Shares Outstanding | 115.12% | 115.12% | 79.29% | 79.60% | 9.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |